ChromaDex Corp. (Los Angeles, CA) expanded its reference standard business with a new line of cannabinoid reference standards available to researchers. Derived from hemp for laboratory use, they include reference standards for cannabidiol (CBD) and cannabidivarin (CBD-V). Reference standards are used as benchmarks to confirm the identity and potency of products. This new line adds to the firm’s existing catalog of 1750 phytochemicals and 400 botanical reference materials.
“In the CBD space, we see an abundance of misinformation and a dearth of quality standards testing,” said Rob Fried, ChromaDex CEO and member of the Board of Directors of the Council for Responsible Nutrition, in a press release. “ChromaDex has been a leader in standards testing for over 20 years, and we look forward to helping bring some scientific integrity to those interested in CBD.”
“We support the establishment of a safe limit of CBD for consumers,” added ChromaDex co-founder and executive chairman Frank Jaksch. “Our tools will help researchers and companies develop quality products that match label claims.”